RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness
RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness
redhill biopharma正在利用BARDA資金推進Opaganib用於埃博拉治療，旨在解決全球衛生應對準備工作。
- The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV)
- The funding advances opaganib's positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV
- Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks
- This year marks the 10th anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO)1
- Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction. It is believed to be the first host-directed molecule to show activity in EBOV in vivo and represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. Additional U.S. government collaborations with opaganib are ongoing
- Significant geopolitical and logistical challenges exist in managing outbreaks of disease and there is an urgent need for safe and effective, oral, small molecule therapeutics that can be stored and easily distributed and administered in an outbreak
- 美國政府的生物醫藥高級研究與發展局（BARDA）選擇了opaganib進行聯合開發和資助，作爲治療埃博拉病毒疾病的醫療對策（MCM）
- 該資助將推動opaganib迄今在預期的FDA動物規則途徑上的積極研發進展，以望獲批准作爲EBOV的MCM
- 最近美國陸軍資助的研究顯示，opaganib在體EBOV模型中顯著提高生存率。BARDA的研究與發展合同爲該合作提供初期資助，以推動opaganib的發展，減輕感染並控制EBOV爆發
- 今年是西非埃博拉疫情爆發十週年，導致11,000人死亡，仍然迫切需要有效且可用的療法。據世界衛生組織（WHO）稱，EBOV導致近一半病例死亡
- Opaganib是一種新型潛在廣譜藥物，顯示出耐變抗病毒和抗炎活性，可能直接影響血管健康，這是EBOV失調的主要靶標之一。它被認爲是首個在EBOV體內展現活性的宿主定向分子，並代表了一種用於生物防禦和全球衛生準備的替代宿主定向治療策略。美國政府與opaganib的合作正在繼續
- 在管理疾病爆發時存在重大的地緣政治和後勤挑戰，急需安全有效的口服小分子治療劑，可以儲存、易於分發和在爆發中使用
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間